Improved quality of life in patients with malignant pleural effusion following videoassisted thoracoscopic talc pleurodesis. Preliminary results

Anticancer Research

Volumn 32, Issue 11, 2012, Pages 5131-5134

  Basso, Stefano M M ^a   Mazza, Francesco ^a   Marzano, Bernardo ^a   Santeufemia, Davide A ^a   Chiara, Giordano B ^a   Lumachi, Franco ^b  

^a S MARIA DEGLI ANGELI HOSPITAL   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

Advanced cancer; Malignant pleural effusion; Quality of life; Talc pleurodesis; Thoracoscopy; VATS

Indexed keywords

TALC;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURGERY; CELLULITIS; CHEST TUBE; CLINICAL ARTICLE; FEASIBILITY STUDY; FEMALE; FEVER; HOSPITALIZATION; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RESEARCH COUNCIL DYSPNEA SCORE; OPERATION DURATION; PATIENT SAFETY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PLEURODESIS; POSTOPERATIVE PAIN; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; SCORING SYSTEM; SURGICAL RISK; SURGICAL TECHNIQUE; VIDEO ASSISTED THORACOSCOPIC SURGERY; VIDEO ASSISTED THORACOSCOPY TALC PLEURODESIS;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PLEURAL EFFUSION, MALIGNANT; PLEURODESIS; QUALITY OF LIFE; TALC; THORACIC SURGERY, VIDEO-ASSISTED;

EID: 84872648163     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Burrows CM, Mathews WC and Colt HG: Predicting survival in patients with recurrent symptomatic malignant pleural effusions: An assessment of the prognostic values of physiologic, morphologic, and quality of life measures of extent of disease. Chest 117: 73-78, 2000.
2. Pilling JE, Dusmet ME, Ladas G and Goldstraw P: Prognostic factors for survival after surgical palliation of malignant pleural effusion. J Thorac Oncol 5: 1544-1550, 2010.
3. Haas AR, Sterman DH and Musani AI: Malignant pleural effusions: Management options with consideration of coding, billing, and a decision approach. Chest 132 : 1036-1041, 2007.
4. van den Toorn LM, Schaap E, Surmont VF, Pouw EM, van der Rijt KC and van Klaveren RJ: Management of recurrent malignant pleural effusions with a chronic indwelling pleural catheter. Lung Cancer 50 : 123-127, 2005.
5. de Campos JR, Varga FS, de Campos Werebe E, Cardoso P, Teixeira LR, Jatene FB and Light RW: Thoracoscopy talc poudrage. A 15-year experience. Chest 119: 801-806, 2001.
6. Janssen JP, Collier G, Astoul P, Tassi GF, Noppen M, Rodriguez- Panadero F, Loddenkemper R, Herth FJ, Gasparini S, Marquette CH, Becke B, Froudarakis ME, Driesen P, Bolliger CT and Tschopp JM: Safety of pleurodesis with talc poudrage in malignant pleural effusion: A prospective cohort study. Lancet 369: 1535-1539, 2007.
7. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW and Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54: 581-586, 1999.
8. Manali ED, Stathopoulos GT, Kollintza A, Kalomenidis I, Emili JM, Sotiropoulou C, Daniil Z, Roussos C and Papiris SA: The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med 102: 586-592, 2008.
9. Lombardi G, Zustovich F, Nicoletto MO, Donach M, Artioli G and Pastorelli D: Diagnosis and treatment of malignant pleural effusion: A systematic literature review and new approaches. Am J Clin Oncol 33: 420-423, 2010.
10. Antunes G, Neville E, Duffy J and Ali N: BTS guidelines for the management of malignant pleural effusions. Thorax 58: ii29-38, 2003.
11. Barbetakis N, Asterious C, Papadopoulou F, Samanidis G, Paliouras D, Kleontas A, Lyriti K, Katsikas I and Tsilikas C: Early and late morbidity and mortality and life expectancy following thoracoscopic talc insufflations for control of malignant pleural effusions: A review of 400 cases. J Cardiothorac Surg 5: 27-33, 2010.
12. Chen H and Brahmer J: Management of malignant pleural effusion. Curr Oncol Rep 10: 287-293, 2008.
13. Rodriguez-Panadero F and Montes-Worboys A: Mechanisms of pleurodesis. Respiration 83: 91-98, 2012.
14. Roberts ME, Neville E, Berrisford RG, Antunes G and Ali NG: Management of a malignant pleural effusion. British Thoracic Society Pleural Disease Guideline 2010. Thorax 65 : ii32-ii40, 2010.
15. Bethune N: Pleural poudrage: New technique for the deliberate production of pleural adhesion as preliminary to lobectomy. J Thorac Surg 4 : 251-261, 1935.
16. Weissberg D and Ben-Zeev I: Talc pleurodesis: Experience with 360 patients. J Thorac Cardiovasc Surg 106 : 689-695, 1993.
17. Maskell NA: Treatment options for malignant pleural effusions. Patient preference does matter. JAMA 307 : 2432-2433, 2012.
18. Doelken P: Management of pleural effusion in the cancer patient. Semin Respir Crit Care Med 31: 734-742, 2010.
19. Dresler CM, Olak J, Herndon JE II, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB and Sugarbaker DJ: Phase III intergroup study of talc poudrage vs. talc slurry sclerosis for malignant pleural effusion. Chest 127: 909-915, 2005.
20. Kolschmann S, Ballin A and Gillissen A: Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest 128 : 1431-1435, 2005.
21. Davies HE, Mishra EK, Kahan BC, Wrightson JM, Stanton AE, Guhan A, Davies CW, Grayez J, Harrison R, Prasad A, Crosthwaite N, Lee YC, Davies RJ, Miller RF and Rahman NM: Effect of an indwelling pleural catheter vs. chest tube and talc pleurodesis for relieving dyspnea in patients with malignant pleural effusion: The TIME2 randomized controlled trial. JAMA 307 : 2383-2389, 2012.